IN BRIEF: RUA Life shares slide as Abiss fall short of earnings target

RUA Life Sciences PLC - holding company of multiple medical device businesses - Expects to report pretax profit of £4.7 million for the 12 months ended September 30. Revenue is expected to rise by 7.8% to £5.5 million from £5.1 million in the final 12 months of the previous 18-month reporting period. Says its contract development and manufacturing operations generate £2.8 million in revenue, while medical device company Abiss records revenue of £1.4 million, below its £1.9 million target, due to inventory reductions at a major customer. RUA Life expects to report adjusted earnings before interest, tax, depreciation and amortisation of around £300,000. Says it continues to evolve and makes good progress in developing its core business. Expects to publish its financial 2026 results towards the end of January.

Current stock price: 23.39 pence, down 8.3% in London on Monday.

12-month change: up 80%

Copyright 2026 Alliance News Ltd. All Rights Reserved.